Summary & Overview
HCPCS Level II J9247: Injection, melphalan flufenamide, 1mg
HCPCS Level II code J9247 designates the injection of melphalan flufenamide, 1 mg, an oncology drug formulation used in systemic chemotherapy. Nationally, accurate coding for high-cost injectable cancer therapies is critical for consistent billing, clinical documentation, and payer coverage determination. HCPCS codes like J9247 enable clear identification of specific drug products and dosing units across care settings.
Key payers addressed in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical context and typical sites of service, plus the types of benchmarks and policy considerations commonly associated with injectable oncology medications: utilization and billing benchmarks, payer coverage patterns, and reimbursement policy updates that affect administration and drug supply billing. The publication also outlines common modifiers and payer reporting practices relevant to infusion services and high-cost drugs.
This resource serves clinicians, billing professionals, and policy analysts seeking concise guidance on the role of HCPCS Level II code J9247 in oncology service lines, payer interactions, and administrative reporting.
Billing Code Overview
HCPCS Level II code J9247 represents the injection of melphalan flufenamide, 1 mg. This code describes a supplied injectable oncology medication used for systemic cancer therapy.
Service Type: Intravenous or parenteral chemotherapy administration
Typical Site of Service: Hospital outpatient infusion center, ambulatory infusion clinic, or oncology specialty clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma receiving systemic oncology care. The patient presents to an outpatient infusion center or hospital oncology infusion unit for administration of melphalan flufenamide (peptidase‑enhanced alkylating agent). Prior to treatment the oncology clinician documents diagnosis, prior therapies, laboratory values (including CBC and renal/hepatic panels), and verifies performance status. A chemotherapy order is written specifying dose in milligrams; pharmacy prepares unit doses and the medication is administered intravenously by an oncology nurse. Observation for infusion‑related reactions and post‑infusion monitoring for cytopenias and other toxicities occurs in the same infusion suite. Typical sites of service include an outpatient hospital infusion center, freestanding oncology infusion clinic, or an inpatient oncology ward for patients requiring admission for complications. Billing uses HCPCS Level II code J9247 reported per 1 mg of melphalan flufenamide, with applicable CPT codes billed separately for infusion administration, evaluation/management if performed, and supportive services (e.g., transfusion) as clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Provider percentage of total surgical or procedural service | When the reporting clinician performed the primary portion of a procedure or service requiring identification of the claim's performing provider (rare for drug infusion; used if professional component is billed). |